Aurobindo Pharma Ltd received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Divalproex Sodium Delayed- Release tablets. The tablets are the generic equivalent of Abbott Laboratories' Depakote Delayed-Release Tablets and fall under the neurological therapeutic category.
The tablets are used for the treatment of the manic episodes associated with bipolar disorder. It is also for monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures and for prophylaxis of migraine headaches.
The product had a market size of approximately $144 million for the 12-month ended September 2010.
Comments
All Comments (0)
Join the conversation